Clinical Trial Update: Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of GSK573719 delivered via a novel dry powder inhaler in chronic obstructive pulmonary disease. Results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK573719

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-02-11